

Bluebird, Gritstone inks deal to develop cancer cell therapies

23 August 2018 | News

Gritstone Oncology will receive \$20M in an upfront payment and an additional \$10M in the form of a Series C preferred equity investment.



Singapore- Bluebird Bio and Gritstone Oncology collaborates to research, develop and commercialize products for the treatment of cancer using cell therapy.

Under the terms of the agreement, Gritstone Oncology will provide 10 tumor-specific targets across several tumor types and, in certain cases, T-cell receptors directed to those targets to Bluebird Bio. Gritstone Oncology will receive \$20M in an upfront payment and an additional \$10M in the form of a Series C preferred equity investment.

In addition, Gritstone Oncology is eligible for significant development, regulatory and commercial milestones on any therapies, and tiered royalties on certain approved therapies.